CN105343366A - Medicine composition, preparing method thereof, preparation thereof and application thereof - Google Patents
Medicine composition, preparing method thereof, preparation thereof and application thereof Download PDFInfo
- Publication number
- CN105343366A CN105343366A CN201510912773.1A CN201510912773A CN105343366A CN 105343366 A CN105343366 A CN 105343366A CN 201510912773 A CN201510912773 A CN 201510912773A CN 105343366 A CN105343366 A CN 105343366A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- ganoderma
- medicine composition
- group
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title abstract description 5
- 229940079593 drug Drugs 0.000 title description 4
- 239000000843 powder Substances 0.000 claims abstract description 40
- 241000222336 Ganoderma Species 0.000 claims abstract description 37
- 239000002775 capsule Substances 0.000 claims abstract description 15
- 239000006187 pill Substances 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 239000008187 granular material Substances 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 68
- 239000002994 raw material Substances 0.000 claims description 15
- 238000010298 pulverizing process Methods 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 239000006196 drop Substances 0.000 claims description 4
- 235000012907 honey Nutrition 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 235000013372 meat Nutrition 0.000 claims description 2
- 235000014347 soups Nutrition 0.000 claims description 2
- 210000005075 mammary gland Anatomy 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 13
- 238000000227 grinding Methods 0.000 abstract description 8
- 206010020718 hyperplasia Diseases 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 241001448411 Dracaena draco Species 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 description 17
- 241000700199 Cavia porcellus Species 0.000 description 13
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 239000000186 progesterone Substances 0.000 description 6
- 229960003387 progesterone Drugs 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 5
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 4
- 102000003946 Prolactin Human genes 0.000 description 4
- 108010057464 Prolactin Proteins 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 229950002007 estradiol benzoate Drugs 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 229940097325 prolactin Drugs 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 206010006256 Breast hyperplasia Diseases 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004883 areola Anatomy 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine composition, a preparing method thereof, a preparation thereof and an application thereof. The medicine composition is composed of dragon tree leaves and lucid ganoderma, and the weight ratio of the dragon tree leaves to the lucid ganoderma is 0.5-1.5:0.5-1.5. The preparing method includes the steps of pretreating, coarse grinding, superfine grinding and mixing. The preparation is characterized in that auxiliary materials which can be accepted in the pharmacy are added into the medicine composition to prepare a powder or a tablet or a granule or a capsule or a dripping pill or a honeyed pill; the application is the application of the medicine composition to preparing medicine for preventing/curing mammary-gland hyperplasia. The medicine composition is prepared in a mixing mode according to the accurately-set formula, compatibility is carried out according to the active compound physics, the chemical property and the contained active ingredients to achieve the effect of curing mammary-gland hyperplasia, and the medicine composition has the advantages of being high in bioavailability, high in active ingredient dissolving-out speed, good in medicine absorption effect and small in side effect.
Description
Technical field
The invention belongs to Chinese drug preparation technique field, be specifically related to a kind of pharmaceutical composition and preparation method thereof, preparation and application.
Background technology
Cyclomastopathy refers to breast epithelium and proliferation of fibrous tissue, mammary gland tissue conduit and newborn lobule degeneration structurally and the growth of Progressive symmetric erythrokeratodermia connective tissue.Be the modal cystic hyperplasia of breast of women, should prevent in advance.The cause of disease is: the bad Nervous and Mental Factors such as 1, spirit is too nervous, emotion is too exciting, the breast hyperplasia tissue that should restore all may be made to can not get restoring or meromorphosis, in the course of time, just form cyclomastopathy, and these bad direct stimulations also can increase the weight of existing cyclomastopathy symptom.2., repeatedly artificial abortion easily sends out cyclomastopathy.3, estrogen definitely or relatively increases, and progestogen are absolute or relatively reduce the breast structure disorder caused.4, long-term taking is containing estrogenic health product, contraceptive, also may cause cyclomastopathy.
Cyclomastopathy has a lot of type, and what have is physiological completely, does not need special handling also can disappear voluntarily, as Simple proliferation of mammary gland, what have is then pathologic, needs active treatment, especially cystic hyperplasia type, owing to there is the possibility of canceration, can not adopt a casual attitude.At present, Therapeutic Method mainly contains to be made regular check on, adheres to taking medicine and Operative total removal etc., and medicine and method can not meet the demand of people in the market, therefore, develops and a kind ofly can solve people and be very important for the Chinese medicine of the demand of cyclomastopathy medicine.
Summary of the invention
The first object of the present invention is to provide a kind of pharmaceutical composition; Second object is the preparation method providing described pharmaceutical composition; 3rd object is the preparation providing described pharmaceutical composition; 4th object is the application providing described pharmaceutical composition.
The first object of the present invention is achieved in that described pharmaceutical composition is made up of sanguis draconis leaves and Ganoderma, and weight ratio is 0.5 ~ 1.5:0.5 ~ 1.5.
The second object of the present invention is achieved in that and comprises pretreatment, coarse pulverization, micronizing and mixture operation, specifically comprises:
A, pretreatment: the foreign material in each raw material are rejected, through selected, cleaning, dry in the sun, to be dried to moisture content≤3% for subsequent use;
B, coarse pulverization: raw material sanguis draconis leaves and Ganoderma are pulverized with Roughpulverizer respectively, crosses 80 ~ 140 mesh sieves for subsequent use;
C, micronizing: the micropowders each raw material after coarse pulverization being obtained respectively each raw material through micronizing;
D, mixture: each raw material micropowders mixture is evenly obtained object by formulation ratio.
The third object of the present invention is achieved in that in described pharmaceutical composition that adding pharmaceutically acceptable adjuvant makes powder, tablet, granule, capsule, drop pill or honey pill agent.
The fourth object of the present invention is achieved in that described pharmaceutical composition is preparing the application in preventing/treating cyclomastopathy medicine.
Cyclomastopathy is due to raw in feelings will is unsuccessful, depressed rage impairing the liver, stagnation of QI due to depression of the liver, QI and blood are condensed newborn network, worry impairing spleen, phlegm-damp, that stagnation of QI expectorant coagulates, blood stasis knot combinate form becomes lump in breast.Sanguis draconis leaves has effect of Qinghuo Jiedu, blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain.The cyclomastopathy that, meridian and vessels obstruction poly-to QI and blood condensation, blood stasis knot causes, pain have obvious curative effects.In prescription of the present invention, Ganoderma enters the heart, liver, lung, kidney channel, has effect of nourishing lung qi, invigorating the liver and kidney.Liver energy store blood, has significant curative effect to the cyclomastopathy that insufficiency of vital energy and blood causes.Ganoderma and sanguis draconis leaves two medicine are share, blood circulation promoting and blood stasis dispelling, using tonifying Qi reinforcing lungs, fundamentally solve cyclomastopathy problem.
Pharmaceutical composition of the present invention is made according to the prescription mixture of accurately setting, carry out compatibility according to former medicine reason, chemical property and contained active component and reach the efficacy effect solving cyclomastopathy, and have that bioavailability is high, active component stripping is fast, drug absorption is effective and the feature that side effect is little.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is further illustrated, but limited the present invention never in any form, and any conversion done based on training centre of the present invention or replacement, all belong to protection scope of the present invention.
Pharmaceutical composition of the present invention is made up of sanguis draconis leaves and Ganoderma, and weight ratio is 0.5 ~ 1.5:0.5 ~ 1.5.
Described pharmaceutical composition is made up of sanguis draconis leaves and Ganoderma, and weight ratio is 1:1.
The preparation method of pharmaceutical composition of the present invention, comprises pretreatment, coarse pulverization, micronizing and mixture operation, specifically comprises:
A, pretreatment: the foreign material in each raw material are rejected, through selected, cleaning, dry in the sun, to be dried to moisture content≤3% for subsequent use;
B, coarse pulverization: raw material sanguis draconis leaves and Ganoderma are pulverized with Roughpulverizer respectively, crosses 80 ~ 140 mesh sieves for subsequent use;
C, micronizing: the micropowders each raw material after coarse pulverization being obtained respectively each raw material through micronizing;
D, mixture: each raw material micropowders mixture is evenly obtained object by formulation ratio.
The particle diameter of described micropowders is 6 ~ 12 μm.
The preparation of pharmaceutical composition of the present invention is add pharmaceutically acceptable adjuvant in described pharmaceutical composition to make powder, tablet, granule, capsule, drop pill or honey pill agent.
The described pharmaceutical composition that is applied as of pharmaceutical composition of the present invention is preparing the application in preventing/treating cyclomastopathy medicine.
Described pharmaceutical composition instructions of taking is for take after mixing it with water with boiled water, Mel or meat soup, and taking dose is 3g/ time.
With specific embodiment, the present invention will be further described below:
Embodiment 1
---the preparation method of described pharmaceutical composition
A, pretreatment: get sanguis draconis leaves 50kg, Ganoderma 50kg, respectively sanguis draconis leaves and Ganoderma are placed in the silt etc. that SUS304 rustless steel XSG-600 type circulating water washer utilizes the rolling friction removing medical material of Water spray and the cleaning of general water and medical material after Ganoderma being struck off Ganoderma foot, drum speed is 12rpm, after medical material foreign material are wherein rejected, choose, shred again, sanguis draconis leaves after chopping is placed in baking oven sterilizing 5min, sterilization time is set as 75 DEG C, Ganoderma sterilization time is 5min, sterilising temp is 75 DEG C, then by Radix Notoginseng, Radix Salviae Miltiorrhizae, Fructus Crataegi is placed in RXH type hot air circular drying machine respectively, be dried to moisture content≤3% for subsequent use.
B, coarse pulverization: sanguis draconis leaves, Ganoderma Circoplex classified grinding machine are pulverized, sanguis draconis leaves, that Ganoderma coarse powder crosses 80 mesh sieves is for subsequent use, and microorganism detection is carried out in sanguis draconis leaves, the sampling of Ganoderma coarse powder, and the coarse powder after qualified carries out micronizing.
C, micronizing: the sanguis draconis leaves after Micro biological Tests is qualified, Ganoderma coarse powder WFM100 type ultra micro vibromill are pulverized, working condition is set as: grinding media is bar-shaped, grinding media diameter is 0.3mm, grinding media pack completeness is 50%, sanguis draconis leaves inventory is 6kg, and grinding time is 6h, and Ganoderma inventory is 6kg, grinding time is 6h, and in the sanguis draconis leaves after pulverizing, Ganoderma micropowders, particle diameter is the fine powder ratio of 6-12um is 92%.After micropowders is crossed 200 mesh sieves, the micropowders having crossed sieve is placed in rustless steel CBS series drawer type permanent-magnetic iron expeller and removes individual metal class material.
D, mixture: by sanguis draconis leaves micropowders 50 parts by weight, Ganoderma micropowders 50 parts mixing, be placed in EYH-1000A type two-dimensional motion mixer mix and blend, rotation number is 8rpm, shake number is 6rpm, mixing time is 30min, after mixture is even, in pharmaceutical composition, particle diameter is the fine powder ratio of 4-14um is 92%.
Embodiment 2
Pharmaceutical composition pack prepared by Example 1 becomes powder.
Embodiment 3
Pharmaceutical composition prepared by Example 1 adds pharmaceutically acceptable adjuvant and makes tablet.
Embodiment 4
Pharmaceutical composition prepared by Example 1 adds pharmaceutically acceptable adjuvant and makes capsule.
Embodiment 5
Pharmaceutical composition prepared by Example 1 adds pharmaceutically acceptable adjuvant and makes granule.
Embodiment 6
Pharmaceutical composition prepared by Example 1 adds pharmaceutically acceptable adjuvant and makes drop pill.
Embodiment 7
Pharmaceutical composition prepared by Example 1 adds pharmaceutically acceptable adjuvant and makes honey pill agent.
Embodiment 8
---treatment cyclomastopathy effect pharmacological evaluation
Experiment material: (1) experimental drug: embodiment 1 prepare pharmaceutical composition of the present invention, sanguis draconis leaves superfine powder, Ganoderma superfine powder, by weight the sanguis draconis leaf powder of 1:2,1:3,3:1,2:1 mixture: dendrobe powder pharmaceutical composition, Rupisanjie capsule, estradiol benzoate injection, testosterone, progesterone, prolactin antagonist.Wherein, sanguis draconis leaf powder is prepared with quality inspection according to the quality standard of " Yunnan Province's prepared slices of Chinese crude drugs standard " (cloud YPBZ-0196-2013) defined, and Ganoderma powder is prepared with quality inspection according to the quality standard of " Chinese Pharmacopoeia " (version in 2010) defined.Rupisanjie capsule is purchased from Jiangxi De Shang pharmaceutical Co. Ltd, and estradiol benzoate injection is purchased from the large Chemical Group in east, Tianjin, and testosterone, progesterone, prolactin antagonist are purchased from Shanghai GM Pharmaceutical.
(2) experimental subject: Adult female unpregnancy Wistar Cavia porcellus 80, body weight 190 ± 10g, is provided (certificate of competency: dynamic No. 3676494th, the word of doctor) by Test Animal Centre, Academy of Military Medical Sciences, P.L.A
(3) experimental facilities: the full-automatic microparticle chemiluminescence immunoassay system of UV-120-02 type spectrophotometer (Japanese Shimadzu Corporation) ACCESS.
Experimental technique:
(1) grouping and modeling
Experimental guinea pig 100, be divided into 10 groups at random, i.e. Normal group, model control group, Rupisanjie capsule group, sanguis draconis leaf powder group, Ganoderma powder group, the sanguis draconis leaf powder of pharmaceutical composition group of the present invention, Different Weight ratio: Ganoderma powder pharmaceutical composition (1:2,1:3,3:1,2:1) group.Except Normal group, all the other are the every Mus intramuscular injection estradiol benzoate 0.5mg/kg of group respectively, once a day, continuous 25d, uses intramuscular injection progesterone injection 5mg/kg instead, once a day then, continuous 5d, now rat nipple occurs red, swollen and increases, and has part mammary areola to occur, rat mammary gland model of hyperplasia is formed.
(2) treat
After modeling success, Normal group and model control group give 0.9% sodium chloride solution each 2ml gavage, once a day, continuous 30d, the dosage of Rupisanjie capsule group is that 0.53g.kg-1(is equivalent to be grown up 5 times of clinical plan dosage), every day 1 time, altogether 30d.Sanguis draconis leaf powder group, Ganoderma powder group, the sanguis draconis leaf powder of pharmaceutical composition group of the present invention, Different Weight ratio: the dosage that Ganoderma powder pharmaceutical composition (1:2,1:3,3:1,2:1) is organized is 0.53g.kg
-1(be equivalent to respectively be grown up clinical plan dosage 5 times).Every day 1 time, altogether 30d.
(3) Testing index
All every rat chest first pair of breast diameter is measured with precision vernier callipers before and after administration.After last administration 24h, the tested Cavia porcellus of sacrificed by decapitation, is about 3ml by abdominal aortic blood, and centrifugalize serum is preserved to be checked under 2-8 DEG C of condition.Radioimmunology is adopted to detect estradiol (E2), progesterone (P) and prolactin antagonist (PRL) level content in serum.Take off chest the 2nd pair of breast mammary gland with 8mm card punch, carry out embedding, cutting into slices, HE dyes, its morphological changes of various tissue components of Microscopic observation, and measures lobules of mammary gland number, acinus number, alveolar lumen diameter and conduit diameter.
(4) date processing
Experimental data x ± s represents, compares and adopt t inspection between group.
(1) on the impact of cyclomastopathy Cavia porcellus breast diameter, breast volume, mammary gland weight change
Table 1 different pharmaceutical is on impact (x ± s) (n=10) of Cavia porcellus breast diameter, breast volume and mammary gland weight
Note: compare with model control group, * P<0.05, * * P<0.01.
From the experimental result of table 1, rats in normal control group udder size is without significant change, and breast is without hypertrophy; The obvious enlargement of model group rats breast, the obvious hypertrophy of mammary gland.Compare with model group, the sanguis draconis leaf powder of Rupisanjie capsule group, sanguis draconis leaf powder group, Ganoderma powder group, pharmaceutical composition group of the present invention and Different Weight ratio: Ganoderma powder pharmaceutical composition (1:2,1:3,3:1,2:1) group, after administration, Cavia porcellus breast diameter breast volume all has and reduces in various degree, mammary gland weight alleviates all in various degree, but, the effect of pharmaceutical composition group of the present invention is the most obvious, comparatively other administration group can significantly reduce breast diameter and breast volume, alleviates mammary gland weight.
(2) on the impact of cyclomastopathy guinea pig serum estradiol (E2), progesterone (P), prolactin antagonist (PRL) content
Table 2 different pharmaceutical is on impact (x ± s) (n=10) of cyclomastopathy guinea pig serum sex hormone level
| Group | E2 | P | PRL |
| Normal group | 16.6±2.5＊＊＊ | 67.7±16.7 | 148.9±10.9 |
| Model control group | 146.5±20.7 | 69.9±10.4 | 137.2±18.4 |
| Rupisanjie capsule group | 116.0±10.3＊＊ | 77.6±16.5 | 140.0±11.3 |
| Pharmaceutical composition of the present invention | 68.0±17.5＊＊＊ | 79.0±10.7 | 139.0±12.5 |
| Pharmaceutical composition (1:2) | 70.0±15.1＊＊＊ | 63.3±13.4 | 142.3±10.3 |
| Pharmaceutical composition (1:3) | 105.4±48.6＊ | 63.4±12.5 | 138.6±15.4 |
| Pharmaceutical composition (2:1) | 116.0±10.4 | 77.7±15.5 | 142.7±10.4 |
| Pharmaceutical composition (3:1) | 105.4±48.6＊ | 64.1±12.3 | 139.5±11.5 |
| Sanguis draconis leaves group | 136.5±20.7 | 63.8±13.5 | 142.6±10.3 |
| Ganoderma powder group | 143.5±20.7 | 63.5±12.5 | 142.2±10.0 |
Note: compare with model control group, * P<0.05, * * P<0.01, * * * P<0.001
From the experimental result of table 2, the blood serum E2 level increase more remarkable in Normal group of model control group Cavia porcellus.Rupisanjie capsule group, sanguis draconis leaf powder group, the sanguis draconis leaf powder of dendrobe powder group, pharmaceutical composition group of the present invention and Different Weight ratio: dendrobe powder pharmaceutical composition (1:2,1:3,3:1,2:1) group, the blood serum E2 level of Cavia porcellus significantly reduces upon administration.Wherein, the effect of pharmaceutical composition of the present invention is the most remarkable, fully can suppress the rising of the cyclomastopathy guinea pig serum E2 level caused by estradiol benzoate and Progesterone.Difference that blood-serum P and PRL level compare with Normal group that there are no significant.
(3) on the impact of cyclomastopathy Cavia porcellus lobules of mammary gland, acinus and gland conduit
Table 3, different pharmaceutical are on cyclomastopathy Cavia porcellus lobules of mammary gland, acinus and gland conduit impact (x ± s) (n=10)
| Group | Every tangent plane lobules of mammary gland number | Every mm2 mammary gland alveolus number |
| Normal group | — | — |
| Model control group | 5.4±1.9 | 199.3±48.2 |
| Rupisanjie capsule group | 4.4±1.2 | 178.8±26.0 |
| Pharmaceutical composition of the present invention | 3.6±1.2＊ | 131.1±33.1＊＊ |
| Pharmaceutical composition (2:1) | 4.1±1.0 | 151.0±29.3＊ |
| Pharmaceutical composition (3:1) | 4.9±1.2 | 177.5±26.0 |
| Pharmaceutical composition (1:2) | 4.1±1.2 | 146.1±36.2＊ |
| Pharmaceutical composition (1:3) | 4.3±1.2 | 151.0±29.0＊ |
| Ganoderma powder group | 4.4±1.1 | 178.5±26.0 |
| Sanguis draconis leaves group | 4.7±1.0 | 146.2±36.2＊ |
| Group | Acinus diameter (um) | Conduit diameter (um) |
| Normal group | — | — |
| Model control group | 45.9±8.2 | 53.5±15.0 |
| Rupisanjie capsule group | 41.1±8.2 | 48.3±12.0 |
| Pharmaceutical composition group of the present invention | 33.2±6.7** | 46.0±11.1 |
| Pharmaceutical composition (2:1) | 36.1±6.2** | 51.9±10.2 |
| Pharmaceutical composition (3:1) | 40.6±8.0 | 44.9﹢9.2 |
| Pharmaceutical composition (1:2) | 37.2±7.2* | 44.8±9.2 |
| Pharmaceutical composition (1:3) | 37.2±7.1* | 46.0±11.0 |
| Ganoderma powder group | 40.5±8.0 | 48.2±12.0 |
| Sanguis draconis leaves group | 40.6±8.1 | 50.9±10.2 |
Note: compare with model control group, * P<0.05, * * P<0.01.
Microscopic observation is visible, and rats in normal control group mammary gland is in quiescent stage state, without proliferative lesion, is mainly fat and connective tissue, and acinus is few, and lobule is not obvious, and gland catheter lumen is without expansion; Model group rats cyclomastopathy is diffusivity, and without local enclosed mass, fat and connective tissue obviously reduce, and acinus and lobule significantly increase, and alveolar lumen and gland catheter lumen are obviously expanded.The sanguis draconis leaf powder of Rupisanjie capsule group, sanguis draconis leaf powder group, Ganoderma powder group, pharmaceutical composition group of the present invention, Different Weight ratio: Ganoderma powder drug regimen
The mammary gland tissue organized of thing (1:2,1:3,3:1,2:1) comparatively model control group changes all in various degree, and wherein, the resisting hyperplasia of mammary glands effect of pharmaceutical composition group of the present invention is the most remarkable.
(3) toxicity test
Utilize rabbit to carry out acute irritation experiment, by the eyes of sample aqueous solution white rabbit side, contralateral eye instillation distilled water compares, and observing respectively at 6h, 24h, 48h after a medicine, is 0 after average eye irritation 48h.Pharmaceutical composition avirulence of the present invention and untoward reaction are described, use safety.
Claims (7)
1. a pharmaceutical composition, is characterized in that described pharmaceutical composition is made up of sanguis draconis leaves and Ganoderma, and weight ratio is 0.5 ~ 1.5:0.5 ~ 1.5.
2. pharmaceutical composition according to claim 1, is characterized in that described pharmaceutical composition is made up of sanguis draconis leaves and Ganoderma, and weight ratio is 1:1.
3. a preparation method for pharmaceutical composition according to claim 1, is characterized in that comprising pretreatment, coarse pulverization, micronizing and mixture operation, specifically comprises:
A, pretreatment: the foreign material in each raw material are rejected, through selected, cleaning, dry in the sun, to be dried to moisture content≤3% for subsequent use;
B, coarse pulverization: raw material sanguis draconis leaves and Ganoderma are pulverized with Roughpulverizer respectively, crosses 80 ~ 140 mesh sieves for subsequent use;
C, micronizing: the micropowders each raw material after coarse pulverization being obtained respectively each raw material through micronizing;
D, mixture: each raw material micropowders mixture is evenly obtained object by formulation ratio.
4. the preparation method of pharmaceutical composition according to claim 3, is characterized in that the particle diameter of described micropowders is 6 ~ 12 μm.
5. a preparation for the pharmaceutical composition described in claim 1 or 2, is characterized in that adding pharmaceutically acceptable adjuvant in described pharmaceutical composition makes powder, tablet, granule, capsule, drop pill or honey pill agent.
6. an application for the pharmaceutical composition described in claim 1 or 2, is characterized in that described pharmaceutical composition is preparing the application in preventing/treating cyclomastopathy medicine.
7. the application of pharmaceutical composition according to claim 6, it is characterized in that described pharmaceutical composition instructions of taking is for take after mixing it with water with boiled water, Mel or meat soup, taking dose is 3g/ time.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510912773.1A CN105343366A (en) | 2015-12-11 | 2015-12-11 | Medicine composition, preparing method thereof, preparation thereof and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510912773.1A CN105343366A (en) | 2015-12-11 | 2015-12-11 | Medicine composition, preparing method thereof, preparation thereof and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105343366A true CN105343366A (en) | 2016-02-24 |
Family
ID=55319524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510912773.1A Pending CN105343366A (en) | 2015-12-11 | 2015-12-11 | Medicine composition, preparing method thereof, preparation thereof and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105343366A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106798854A (en) * | 2017-03-17 | 2017-06-06 | 广东说养自然医学技术有限公司 | Emblic mulberry leaf piece and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1660344A (en) * | 2005-01-11 | 2005-08-31 | 北京亚东生物制药有限公司 | Combination of medication for treating disease of hyperplasia of mammary glands glands and preparation method |
| CN101167761A (en) * | 2006-10-29 | 2008-04-30 | 宜兴市鹏鹞天然保健营养素有限公司 | Application of glossy ganoderma wall damaged spore powder and glossy ganoderma spore oil in treating woman mastoproliferation |
| CN103800690A (en) * | 2014-02-20 | 2014-05-21 | 普洱淞茂制药股份有限公司 | Dragon tree leaf/dendrobe pharmaceutical composition, and preparation method, preparation and application thereof |
-
2015
- 2015-12-11 CN CN201510912773.1A patent/CN105343366A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1660344A (en) * | 2005-01-11 | 2005-08-31 | 北京亚东生物制药有限公司 | Combination of medication for treating disease of hyperplasia of mammary glands glands and preparation method |
| CN101167761A (en) * | 2006-10-29 | 2008-04-30 | 宜兴市鹏鹞天然保健营养素有限公司 | Application of glossy ganoderma wall damaged spore powder and glossy ganoderma spore oil in treating woman mastoproliferation |
| CN103800690A (en) * | 2014-02-20 | 2014-05-21 | 普洱淞茂制药股份有限公司 | Dragon tree leaf/dendrobe pharmaceutical composition, and preparation method, preparation and application thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106798854A (en) * | 2017-03-17 | 2017-06-06 | 广东说养自然医学技术有限公司 | Emblic mulberry leaf piece and preparation method thereof |
| CN106798854B (en) * | 2017-03-17 | 2020-10-09 | 广东说养自然医学技术有限公司 | Phyllanthus emblica leaf and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105999159B (en) | Brown sugar and saussurea involucrata composition and preparation method thereof | |
| CN104873624B (en) | A kind of pharmaceutical composition for gouty arthritis | |
| CN102362950A (en) | Traditional Chinese medicine for treating leucoderma | |
| CN103800690B (en) | A kind of sanguis draconiss leaveves, Herba Dendrobii pharmaceutical composition and preparation method thereof, preparation and application | |
| CN105663643A (en) | Traditional Chinese medicine composition for treating liver-kidney yin deficiency and preparation method thereof | |
| CN103877486A (en) | Medicine for promoting rise of hemameba number after radiotherapy and chemotherapy and preparation method thereof | |
| CN105343366A (en) | Medicine composition, preparing method thereof, preparation thereof and application thereof | |
| CN103041306B (en) | Traditional Chinese medicine composition for curing climacteric syndrome of women and preparation method thereof | |
| CN109528917B (en) | Korean medicinal composition for treating rheumatoid arthritis and preparation method of cream thereof | |
| CN102430097A (en) | Traditional Chinese medicine for treating leucoderma | |
| CN102552729B (en) | Medicament for treating mesangial proliferative glomerulonephritis | |
| CN101897933A (en) | Chinese patent medicament for treating leucoderma | |
| CN105748646A (en) | Traditional Chinese medicine composition for treating pain in neck or shoulders or waist or legs and preparation method thereof | |
| CN105902951A (en) | Traditional Chinese medicinal compound for treating osteosarcomas on basis of chemotherapeutic drugs | |
| CN104888104A (en) | Pharmaceutical composition for nursing and treating varicose veins and preparation method of pharmaceutical composition | |
| CN104510972A (en) | Traditional Chinese medicinal composition for treating asthma and preparation method of traditional Chinese medicinal composition | |
| CN104721366B (en) | A kind of Chinese medicine composition and its application | |
| CN104001140A (en) | Paste for treating PICC (Peripherally Inserted Central Catheter) phlebitis and preparation method thereof | |
| CN102716424A (en) | Breast nodule treatment medicine composition and preparation process and application thereof | |
| CN108310159A (en) | A kind of plaster of blood pressure lowering and preparation method thereof | |
| CN105362396A (en) | Pharmaceutical composition and preparation method, preparation and application thereof | |
| CN105770134A (en) | Traditional Chinese medicine for treating hyperlipemia | |
| CN118717785A (en) | A pharmaceutical composition for preventing and treating scar hyperplasia, and its preparation method and application | |
| CN113318152A (en) | External composition for regulating estrogen secretion and preparation method and application thereof | |
| CN115919939A (en) | Traditional Chinese medicine composition for treating hyperplasia of mammary glands and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 665000 Yunnan province city Simao district is the wood River Industrial Park Applicant after: Six kinds of pharmaceutical Limited by Share Ltd Address before: 665000 Simao province Yunnan city Simao District of Puer City wood is the River Industrial Park Applicant before: Pu'er Songmao Pharmaceutical Co., Ltd. |
|
| CB02 | Change of applicant information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160224 |
|
| RJ01 | Rejection of invention patent application after publication |